Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

FddA demonstrates anti-HIV activity at well-tolerated doses in phase I trial

Feb. 5, 1998

Pharmacokinetics and drug interactions for Fortovase

Feb. 5, 1998

PNU-140690: clinical pharmacokinetics and safety after single and multiple doses

Feb. 5, 1998

Multiple-dose phase I trial of FP-21399 in HIV discussed at AIDS conference

Feb. 5, 1998

Early clinical results support potential of ABT-378/ritonavir combination

Feb. 5, 1998

Warner-Lambert presents SAR for potent, nonpeptide HIV protease inhibitor at AIDS conference

Feb. 5, 1998

Calanolide A well tolerated in phase I trials

Feb. 5, 1998

Continued HIV suppression requires triple drug maintenance therapy

Feb. 4, 1998

PRO-2000 gel well tolerated in phase I trial in healthy females

Feb. 4, 1998

Phase III trial compares immediate and delayed treatment with fomivirsen for CMV retinitis

Feb. 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...